Home » Stocks » IMTX

Immatics N.V. (IMTX)

Stock Price: $11.60 USD -0.18 (-1.53%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
Market Cap 731.00M
Revenue (ttm) 31.62M
Net Income (ttm) -242.34M
Shares Out 62.91M
EPS (ttm) -21.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $11.60
Previous Close $11.78
Change ($) -0.18
Change (%) -1.53%
Day's Open 11.73
Day's Range 11.53 - 11.96
Day's Volume 48,367
52-Week Range 8.66 - 18.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...

3 weeks ago - GlobeNewsWire

Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting...

1 month ago - GlobeNewsWire

Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca...

2 months ago - GlobeNewsWire

Investors liked the company's latest clinical update.

3 months ago - The Motley Fool

A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.

3 months ago - InvestorPlace

Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data...

3 months ago - Benzinga

bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.

Other stocks mentioned: BLUE, HUGE, ONTX
3 months ago - Benzinga

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...

Other stocks mentioned: FGEN, REPL
3 months ago - Benzinga

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
IMTX
Full Company Profile

Financial Performance

In 2020, Immatics's revenue was $31.25 million, an increase of 69.40% compared to the previous year's $18.45 million. Losses were -$229.06 million, 625.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 23.75, which is an increase of 104.74% from the latest price.

Price Target
$23.75
(104.74% upside)
Analyst Consensus: Strong Buy